Company intelligence / Profile preview

AMCKAUS Pharm

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

AMCKAUS Pharm is a South Korean biotechnology company focused on the development of innovative metabolic disease treatments. The company specializes in multi-agonist therapies targeting the GLP-1, GIP, and glucagon receptors to address conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH). By leveraging advanced medicinal chemistry, AMCKAUS Pharm aims to develop next-generation small molecule and peptide-based therapeutics with improved efficacy and safety profiles. The company is currently advancing its lead programs through the pre-clinical stage with the goal of entering clinical trials.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on AMCKAUS Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMCKAUS Pharm.

Explore the full profile